Sera Prognostics (SERA) Expected to Announce Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) will likely be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Sera Prognostics to post earnings of ($0.19) per share and revenue of $0.10 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Performance

Sera Prognostics stock opened at $3.28 on Monday. The business’s fifty day moving average is $3.21 and its two-hundred day moving average is $2.71. The firm has a market cap of $123.56 million, a P/E ratio of -3.86 and a beta of 0.97. Sera Prognostics has a 52 week low of $1.37 and a 52 week high of $9.13.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 21,158 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total value of $66,647.70. Following the transaction, the chief executive officer directly owned 811,136 shares in the company, valued at $2,555,078.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have sold 50,631 shares of company stock worth $153,604. Insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors have recently modified their holdings of SERA. Captrust Financial Advisors raised its position in shares of Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after acquiring an additional 100,366 shares during the period. Corient Private Wealth LLC increased its holdings in shares of Sera Prognostics by 73.9% in the second quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after acquiring an additional 42,500 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Sera Prognostics during the second quarter worth about $92,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SERA has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.